type II is globally very common, yet neglected. Inhibition of dipeptidyl peptidase–4 by DPP–4 inhibitors enhances hormonal activity of incretins (GLP–1, GIP, GRP), stimulates insulin release
Saxagliptin is an orally active, highly potent, selective and competitive dipeptidyl peptidase (DPP)-4 inhibitor used in the treatment of type 2 diabetes mellitus at doses
tested but the difference reached significance only with 63 aconsequence of an inhibition of DPP-4. An inhibition of alpha-glucosidase in duodenum but not in jejunum was observed after
variety of boronic acids were used for Suzuki-Miyaura coupling with commercially-available SiliaCat®DPP-Pd heterogeneous catalyst. Use of this catalyst ensures minimal leaching of palladium in the product
approaches in dietary intervention and fooddrug therapies for type 2 diabetes management by inhibiting DPP IV activity and increasing the half-life of incretin hormones. From the nutrition perspective
stop) movement of the malady. Three classes of diabetes drugs – GLP-1 agonists, DPP-4 inhibitors, and SGLT2 inhibitors–are additionally thought to slow the movement of diabetic nephropathy. Diabetic
variety of boronic acids were used for Suzuki-Miyaura coupling with commercially-available SiliaCat®DPP-Pd heterogeneous catalyst. Use of this catalyst ensures minimal leaching of palladium in the product
Vildagliptin is an anti-diabetic drug under new class of dipeptidyl peptidase-4(DPP-4) inhibitor. The proposed work is performed to develop simple reverse phase liquid chromatographic method
this study was to determine the frequency of use of Dipeptidyl-peptidase inhibitor (DPP-4 inhibitors) in the prescription by the doctors. Doctors are not so convinced and familiar with
behavior of Fexinidazole is studied by employing Cyclic Voltammetry (CV) and Differential Pulse Polarography (DPP) in universal buffers of PH ranging from 2.0 to 12.0. The kinetic parameters such
respectively. This disparity is expected since mJT is a function of Pp and DPp, for a small pressure decrease originating at 1atm pressure. There is also a concordance
specifically CYP3A4), which increases the therapeutic action of many oral hypoglycemic agents (inhibitors of DPP 4, sodium-glucose cotransporter inhibitors). The therapeutic action is also reduced by the decrease
oral hypoglycemic agents was 26.8 kg/m2. The oral hypoglycemic agents consisted of DPP- 4 inhibitors in 7 patients, SGLT2 inhibitors in 3, and metformin
UFLC method was established for determining Linagliptin in Active Pharmaceutical Ingredients. Linagliptin is a DPP-4 inhibitor developed by BoehringerIngelheim (German Pharmaceutical Company) for treatment of type II…
diseases, as it showed many studies (the Finnish Diabetes Prevention Study, Diabetes Prevention Program (DPP), the China Da Qing Diabetes Prevention Study, etc.) Therefore, the aim of our study
intestinal juice ensured controlled release in the intestine. Bioactivities like lipase, cholesteryl esterase and DPP-IV inhibition were higher in encapsulated catechin than free catechin upon simulated gastric and…
present study aimed to evaluate effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4I), on cognitive functions in elderly diabetic patients with and without cognitive impairment. Methods: 253 elderly
Sitagliptin is an oral hypoglycemic agent of the dipeptidyl peptides-4 (DPP-4) enzyme inhibitor used in the treatment of type 2 diabetes mellitus. It acts by stimulating the insulin
metformin in patients with GFR <60 ml/min/1.73 m2. DPP-4 inhibitors do not interact with immunosuppressant drugs and have demonstrated safety in small clinical trials
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.